Our Studies and Partners

The aViation Study

This is a clinical trial looking at the use of a vasopressin receptor antagonist, RO5285119, to improve social and communicative behaviors in autism. This is a 6-month, placebo-controlled trial where subjects may be randomized to placebo, a low dose, or a high dose of the study medication. Two-thirds of subjects enrolled in this study will receive the study medication. We are currently enrolling high-functioning kids and teens (ages 5-17) with autism for this study. Please contact Felicia Widjaja ([email protected], 415-476-7803) or Tracy Warren at ([email protected], 415-476-8803) for more information on this study.

UCSF Dyslexia Center

Leading the way from basic neuroscience research to the classroom: individualized and strength-based approach.

Charles Armstrong School Outcome Study

The partnership between the UCSF Dyslexia Center and the Armstrong School Outcome Study is a collaboration with UCSF Dyslexia Center that studies the cognitive and neurodevelopmental basis for dyslexia and other learning disorders with students at Charles Armstrong School. Our goal is to translate research into personalized treatments. Working with educators, we aim to develop best practice protocols to implement these interventions in classrooms throughout the country.

Oak Hill School Outcome Study

Providing the highest quality of care through integrating educational, medical, and psychosocial assessment and treatment individualized for each student.

This study involves the collaboration between UCSF and Oak Hill School, a non-public school for students with autism and related neurodevelopmental disorders. The purpose of this study is to develop an integrated, comprehensive, and collaborative approach to providing care to children and adolescent with autism, which is crucial to developing evidence-based targeted treatments in a school setting.

Through a partnership between UCSF and the Oak Hill School (OHS), our goal is to build a translational education/medical intervention center for people with significantly impairing neurological disorders that provides integrated, practical, school-based interventions and resilience strengthening therapies and demonstrate significantly improved outcomes.

The Oak Hill School is a therapeutic community specializing in innovative intervention for students with ASD and other neurodevelopmental differences. Our students receive individualized academic instruction tailored to their needs. Health and mental health professionals, speech and language pathologists, and occupational therapists collaborate with classroom teaching teams to implement a comprehensive, integrated program. We measure outcomes regularly and adjust the program to maximize each child’s educational, social and health functioning. Health promoting and biomedical interventions are offered to maximize each child’s ability to learn.

The UCSF medical research team has developed an easy to use, web-based outcome measurement system that makes it possible to track outcomes and better tailor interventions to the individual student. The UCSF team is partnering with parents and health care professionals to implement a health and resilience program in the school. Together, OHS and UCSF are pioneering collaborative and personalized research and innovation to improve the quality of life for our students and other students like them.

A Double-Blind Placebo-Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin

This is a clinical research study using a digestive enzyme for the treatment of children with autism ages 3-8. CM-AT is an enzyme which is similar to the digestive enzymes produced by the pancreas. It is taken 3 times a day, sprinkled over food. It is expected that CM-AT will help improve autistic symptoms through a positive impact on gastrointestinal function. We are no longer enrolling for this study.